8-K/A 1 admd_8ka-16395.htm ADVANCED MEDICAL ISOTOPE CORP. 8-K/A, AMENDMENT NO. 1 admd_8ka-16395.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K /A
Amendment No. 1
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): April 30, 2015
 
 
ADVANCED MEDICAL ISOTOPE CORPORATION 
(Exact name of registrant as specified in its charter)
 
Delaware
000-53497
80-0138937
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
1021 N. Kellogg Street, Kennewick, WA 99336
(Address of principal executive offices and zip code)
 
Registrant’s telephone number, including area code: (509) 736-4000
 
N/A
(Former name or former address, if changed since last report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
1
 
 
Item 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.
 
The Company had the following press release on April 30, 2015 and has attached two forms of correspondence referenced therein.
 
 
Item 9.01 Financial Statements and Exhibits.
 
Exhibit No.
Description
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 
2
 


 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
 
     
 
ADVANCED MEDICAL ISOTOPE CORPORATION
     
Date: May 1, 2015
By:
/s/ James C. Katzaroff
   
James C. Katzaroff
   
Chairman and Chief Executive Officer
 








 
 
 
 
 
 
 
 
 
 
 
 
 
 

3